Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Century Therapeutics Inc (NASDAQ: IPSC) was $0.75 for the day, down -1.24% from the previous closing price of $0.76. In other words, the price has decreased by -$1.24 from its previous closing price. On the day, 1.18 million shares were traded.
Ratios:
Our analysis of IPSC’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 10.39 and its Current Ratio is at 10.39. In the meantime, Its Debt-to-Equity ratio is 0.28 whereas as Long-Term Debt/Eq ratio is at 0.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rodman & Renshaw on August 08, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On August 28, 2023, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $28 to $5.
On December 27, 2022, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $19.Chardan Capital Markets initiated its Buy rating on December 27, 2022, with a $19 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 18 ’25 when Pfeiffenberger Brent sold 34,712 shares for $0.78 per share. The transaction valued at 27,179 led to the insider holds 1,192,545 shares of the business.
Pfeiffenberger Brent bought 34,712 shares of IPSC for $27,166 on Feb 18 ’25. On Feb 03 ’25, another insider, Farid Adrienne, who serves as the Chief Operations Officer of the company, sold 1,054 shares for $0.78 each. As a result, the insider received 822 and left with 134,076 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 23.67 while its Price-to-Book (P/B) ratio in mrq is 0.32.
Stock Price History:
Over the past 52 weeks, IPSC has reached a high of $5.51, while it has fallen to a 52-week low of $0.68. The 50-Day Moving Average of the stock is -22.92%, while the 200-Day Moving Average is calculated to be -58.28%.
Shares Statistics:
A total of 84.76M shares are outstanding, with a floating share count of 36.25M. Insiders hold about 57.37% of the company’s shares, while institutions hold 31.62% stake in the company.
Earnings Estimates
The market rating of Century Therapeutics Inc (IPSC) is currently shaped by the ongoing analysis conducted by 4.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.42 and low estimates of -$0.46.
Analysts are recommending an EPS of between -$1.45 and -$1.66 for the fiscal current year, implying an average EPS of -$1.59. EPS for the following year is -$1.83, with 5.0 analysts recommending between -$1.63 and -$1.98.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 4 analysts. It ranges from a high estimate of $2M to a low estimate of $100k. As of the current estimate, Century Therapeutics Inc’s year-ago sales were $268k
A total of 6 analysts have provided revenue estimates for IPSC’s current fiscal year. The highest revenue estimate was $4.4M, while the lowest revenue estimate was $2.52M, resulting in an average revenue estimate of $3.29M. In the same quarter a year ago, actual revenue was $2.23M
